Table 2.
The enriched metabolic pathways associated with MAFLD (lipidomics).
| Metabolic Pathway | Significant Overlap 1 | Adj. p-Value 2 | Biological Process |
|---|---|---|---|
| Tyrosine metabolism | 3 | 2.61 × 10−3 | Amino acid metabolism |
| Arachidonic acid metabolism | 6 | 8.81 × 10−4 | Arachidonic acid metabolism |
| Prostaglandin formation from arachidonate | 5 | 1.24 × 10−3 | |
| Leukotriene metabolism | 5 | 1.79 × 10−3 | |
| Glycerophospholipid metabolism | 12 | 7.07 × 10−4 | |
| Glycosphingolipid metabolism | 3 | 2.10 × 10−2 | |
| Bile acid biosynthesis | 4 | 5.15 × 10−2 | Bile acid metabolism |
| C21-steroid hormone biosynthesis and metabolism | 7 | 3.09 × 10−3 | |
| Sialic acid metabolism | 3 | 3.20 × 10−3 | Carbohydrate metabolism |
| Fatty acid activation | 6 | 6.85 × 10−4 | Lipid metabolism |
| De novo fatty acid biosynthesis | 7 | 8.03 × 10−4 | |
| Fatty acid Metabolism | 4 | 2.71 × 10−3 | |
| Carnitine shuttle | 4 | 1.69 × 10−2 | |
| Linoleate metabolism | 3 | 1.79 × 10−2 | |
| Vitamin E metabolism | 5 | 1.65 × 10−2 | Metabolism of vitamin E |
1 Number of significant metabolites; 2 the adjusted p-Values were calculated to estimate the false discovery rate. Pathways with ≥3 significant metabolites and FDRs of <20% were considered.